While others have proposed the use of oHSV and RAGE-targeting therapies such as anti-RAGE peptides40 and soluble RAGE41,42 as individual cancer treatment modalities, the combination into a single therapeutic has not been explored for GBM therapy. This evidence concerns the gene AGER and cancer.